Muna Therapeutics Announces CEO Transition as Clinical Pipeline Advances

Rhea-AI Summary

Muna Therapeutics announced a CEO transition as its neurodegeneration pipeline advances. Founding CSO and CEO Rita Balice-Gordon will step down and join the Board, while former iTeos Therapeutics (NASDAQ: ITOS) President & CEO Michel Detheux becomes CEO effective June 29, 2026.

Muna's lead TREM2 agonist MNA-001 is completing Phase 1 and is expected to enter Phase 2 studies in early Alzheimer's in early 2027. Detheux previously led iTeos from spin-off to public company, raising over $1.2B and securing a $2B GSK collaboration. Muna recently used its MiND-MAP platform to publish Nature Medicine data on microglial state transitions in Alzheimer's.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Positive

• Lead TREM2 agonist MNA-001 completing Phase 1, targeting Phase 2 in early 2027
• New CEO Michel Detheux previously raised over $1.2B while leading iTeos
• Prior iTeos $2B GSK collaboration underscores Detheux's strategic partnering track record
• Founding CEO Rita Balice-Gordon remains on the Board, supporting leadership continuity
• MiND-MAP platform findings on microglial state transitions published in Nature Medicine

Negative

• CEO transition introduces executive leadership change effective June 29, 2026

What This Means

This announcement highlights a leadership transition while Muna’s TREM2 agonist advances toward Phas...

Analysis

This announcement highlights a leadership transition while Muna’s TREM2 agonist advances toward Phase 2 in early Alzheimer’s. The incoming CEO’s history of raising over $1.2B and securing a $2B deal is notable; execution on upcoming trials remains a key risk to monitor.

Key Figures

Phase 1 status: Phase 1 Planned Phase 2 start: early 2027 CEO tenure start: 2021 +5 more

8 metrics

Phase 1 status Phase 1 MNA-001 currently completing Phase 1

Planned Phase 2 start early 2027 Phase 2 in early Alzheimer’s planned for early 2027

CEO tenure start 2021 Founding CSO and CEO since 2021 stepping down to Board

Leadership experience more than 30 years Incoming CEO’s biotech leadership experience

Capital raised more than $1.2B Capital raised at prior company under incoming CEO

Employee base 180 employees Team size at previous company led by incoming CEO

Strategic collaboration $2B collaboration Scale of prior GSK alliance led by incoming CEO

Phase 2 target indication early Alzheimer’s MNA-001 planned Phase 2 population

Regulatory & Risk Context

Short Interest: 2.09%

Short Interest

2.09% of float

0% 15% 30%+

low as of 2025-08-29 Days to cover: 1

Short positioning appears relatively low, indicating limited squeeze potential and only modest incremental volatility from short-covering activity.

Key Terms

trem2 agonist, phase 1, phase 2, clinical-stage

4 terms

trem2 agonist medical

"Muna's lead asset, MNA-001, is a best-in-class small-molecule TREM2 agonist"

A TREM2 agonist is a drug designed to activate the TREM2 protein on brain immune cells, effectively 'pressing a switch' that tells those cells to clear waste and support healthy brain tissue. Investors watch these drugs because they target underlying disease processes rather than just symptoms, so successful candidates can change clinical outcomes, create large treatment markets, and carry high value — but they also face costly trials and regulatory risk.

phase 1 medical

"MNA-001 ... is completing Phase 1 and is on track to begin Phase 2 testing"

Phase 1 is the first stage of testing a new drug or medical treatment in people, focused primarily on safety, how the body handles the product, and finding a tolerated dose. Think of it as a short, tightly controlled experiment with a small group to check for dangerous side effects before wider testing; for investors it is an early milestone that reduces some uncertainty but still carries high risk and potential for both big value changes and setbacks.

phase 2 medical

"on track to begin Phase 2 testing in early Alzheimer's patients in early 2027"

Phase 2 is the mid-stage clinical trial where a new drug or treatment is tested in a larger group of patients to see if it works and to keep checking safety after initial human testing. Think of it as a field test that proves whether a product actually delivers its promised benefit. Investors watch Phase 2 closely because its results strongly influence a medicine’s chances of reaching the market, the size of its potential sales, and the company’s valuation.

clinical-stage medical

"Muna has evolved into a clinical-stage company with a differentiated discovery platform"

Clinical-stage describes a drug, therapy, or company whose product is being tested in human trials but has not yet received regulatory approval. For investors, it signals that the project has moved beyond lab work into real-world testing—meaning higher potential reward if trials succeed but also clear risks from trial setbacks, costs, and regulatory delay; think of it like a prototype car on public road tests that could either prove its value or reveal problems that stop it from reaching production.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

After leading Muna's evolution into a clinical-stage company, Rita Balice-Gordon, Ph.D., will step down and join the Board of Directors; former iTeos President & CEO Michel Detheux, Ph.D., appointed Chief Executive Officer

     Company remains focused on developing new therapies to treat neurodegenerative diseases like Alzheimer's, Parkinson's, and ALS, with lead TREM2 agonist on track to enter Phase 2 studies in early Alzheimer's in early 2027

COPENHAGEN, Denmark and BOSTON, June 30, 2026 /PRNewswire/ -- Muna Therapeutics (Muna), a biotechnology company pioneering novel therapeutics for neurodegenerative diseases, today announced a CEO transition. Rita Balice-Gordon, Ph.D., Muna's founding CSO and CEO since 2021, will step down and join the Company's Board of Directors. Michel Detheux, Ph.D., a seasoned biotech entrepreneur and former President and CEO of iTeos Therapeutics (NASDAQ: ITOS), has been appointed CEO, effective June 29, 2026.

Under Balice-Gordon's leadership, Muna has evolved into a clinical-stage company with a differentiated discovery platform and dynamic pipeline focused on neurodegenerative diseases. Muna's lead asset, MNA-001, is a best-in-class small-molecule TREM2 agonist that is completing Phase 1 and is on track to begin Phase 2 testing in early Alzheimer's patients in early 2027. As the company continues to progress, Detheux's experience leading biotechs, advancing innovative therapies and forging strategic alliances will help build on this momentum.    

"It has been one of the greatest privileges of my career to build Muna and lead such a talented team dedicated to bringing hope to patients living with neurodegenerative disease," said Balice-Gordon. "I am extraordinarily proud of what we have accomplished together: advancing MNA-001 toward Phase 2 clinical development; establishing our innovative MIND-MAP discovery platform grounded in human biology; and building a world-class team. I look forward to continuing to support Muna as a member of the Board and am excited to see the company continue to grow under Michel's leadership."

Detheux brings more than 30 years of biotech leadership experience to this role. As the founder and President & CEO of iTeos, he led the company from a research spin-off to a publicly traded clinical-stage entity, raising more than $1.2B and expanding to 180 employees across the US and Europe. Under his leadership, the company also advanced multiple development programs and established significant strategic partnerships, including a $2B collaboration with GSK.    

"Rita and the team have built a platform and pipeline unlike anything else in neurodegeneration," said Michel Detheux, Ph.D., incoming Chief Executive Officer. "Their exceptional work has yielded a compelling clinical asset in the TREM2 agonist program and a major validation of the MiND-MAP platform through the GSK alliance, a partnership model I know well. I am honored to take the helm at this moment and work alongside the team to advance Muna's promising pipeline for people living with neurodegenerative diseases."

"On behalf of the entire Board, I want to express our profound gratitude to Rita for her leadership in shaping Muna into the company it is today," said Donald Nicholson, Ph.D., Chair of Muna's Board of Directors. "Her scientific vision, drive, and deep commitment to patients have been foundational to what we have achieved. We are delighted that she will continue to contribute her unique perspective as a Board member and extremely pleased to welcome Michel, whose business experience and acumen will be instrumental in guiding Muna through future clinical and corporate milestones."

The announcement comes as Muna pushes its small molecule TREM2 agonist program to Phase 2 clinical evaluation and prepares for continued progress across its pipeline of novel neurodegeneration targets. In June, the company published a study in Nature Medicine, in which it leveraged its MiND-MAP platform to identify a critical tipping point in microglial response to amyloid and tau pathology, pinpointing microglial state transitions as key drivers of Alzheimer's.

About Muna Therapeutics

Muna Therapeutics discovers and develops therapies that slow or stop devastating neurodegenerative diseases including Alzheimer's and Parkinson's disease. These disorders impact memory, movement, language, behavior and personality, resulting in disability and death of millions of patients around the globe. Muna focuses its groundbreaking science on identifying new medicines to preserve cognition and other brain functions, enhance resilience to disease pathology, and slow or stop the progression of neurodegenerative diseases. Its name reflects this focus: Muna means 'to remember' in Old Norse. Muna is headquartered in Copenhagen, Denmark, and has operations in the United States. For more information, visit www.munatherapeutics.com. Follow Muna on LinkedIn.

Media Contact:

Lia Dangelico
Deerfield Group
lia.dangelico@deerfieldgroup.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/muna-therapeutics-announces-ceo-transition-as-clinical-pipeline-advances-302813549.html

SOURCE Muna Therapeutics

FAQ

What CEO transition did Muna Therapeutics announce on June 30, 2026?

Muna Therapeutics announced that founding CEO Rita Balice-Gordon will step down and join the Board, while Michel Detheux becomes Chief Executive Officer. According to Muna, the change is effective June 29, 2026, aligning leadership with the company’s advancing clinical-stage neurodegeneration pipeline.

Who is Michel Detheux, the new CEO of Muna Therapeutics linked to NASDAQ: ITOS?

Michel Detheux is a biotech leader and former President & CEO of iTeos Therapeutics (NASDAQ: ITOS). According to Muna, he led iTeos from research spin-off to public clinical-stage company, raising more than $1.2B and securing a $2B collaboration with GSK.

When is Muna Therapeutics' TREM2 agonist MNA-001 expected to start Phase 2 trials?

MNA-001 is expected to enter Phase 2 studies in early Alzheimer's in early 2027. According to Muna, the small-molecule TREM2 agonist is currently completing Phase 1 as the company advances its clinical pipeline in neurodegenerative diseases.

How does Muna Therapeutics' MiND-MAP platform support its Alzheimer's drug discovery?

MiND-MAP underpins Muna’s discovery approach by grounding targets in human biology. According to Muna, the platform recently enabled a Nature Medicine study identifying a critical tipping point in microglial responses to amyloid and tau, highlighting microglial state transitions as key Alzheimer's disease drivers.

What role will former CEO Rita Balice-Gordon have at Muna Therapeutics after stepping down?

Rita Balice-Gordon will transition from CEO to a seat on Muna’s Board of Directors. According to Muna, she will continue contributing her scientific vision and patient-focused perspective while Michel Detheux assumes day-to-day executive leadership of the company.

What does the CEO change mean for Muna Therapeutics' neurodegenerative disease strategy?

Muna states it remains focused on therapies for Alzheimer’s, Parkinson’s, and ALS despite the CEO change. According to Muna, Detheux’s experience advancing innovative therapies and forging alliances is expected to help progress MNA-001 and the broader neurodegeneration-focused pipeline.